PerpEquities

Iovance Biotherapeutics, Inc. (IOVA) balance sheet

NASDAQ · Healthcare · Biotechnology · 975 employees · CEO Frederick G. Vogt

Price
$8.48 -11.30%
Market cap
$3.84B
Enterprise value
$3.78B
Last report
Q2 '26 filed 2026-08-06
Next report
2026-11-05 EPS est. -$0.08

At the end of Q2 '26 Iovance Biotherapeutics, Inc. (IOVA) held $298M in cash and short-term investments against $46M of debt incl. leases. Total assets $916M, total liabilities $179M, shareholders' equity $736M.

Balance sheet

Balance sheetTrendQ3 '23Q4 '23Q1 '24Q2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26
Assets
Cash & equivalents$268M$115M$134M$229M$164M$116M$172M$132M$158M$163M$197M$111M
Short-term investments$93.7M$165M$222M$184M$233M$208M$188M$169M$143M$134M$117M$187M
Receivables$0$151K$234K$31.6M$55.8M$69.3M$70.9M$59.9M$66.8M$82.4M$81.8M$102M
Inventory$9.2M$10.4M$17.6M$27.9M$38.6M$51.5M$65.5M$49.8M$51.7M$51.7M$58.4M$55.6M
Other current assets$12M$17.5M$11.5M$10.2M$6.74M$12.4M$16.5M$11.5M$9.82M$11.6M$12.9M$8.87M
Current assets$383M$308M$386M$482M$499M$457M$513M$423M$429M$443M$467M$464M
Property, plant & equipment (net)$179M$177M$183M$180M$179M$164M$162M$172M$175M$177M$176M$175M
Long-term investments$0$66.4M$0$6.36M$6.36M$0$0$0$5.97M$0$0$0
Intangible assets$224M$229M$294M$295M$307M$282M$285M$296M$285M$279M$269M$264M
Other non-current assets$66.7M$270K$6.69M$327K$280K$6.73M$6.25M$16.3M$9.27M$14.1M$14.3M$12.4M
Non-current assets$470M$473M$484M$482M$493M$453M$454M$485M$476M$470M$459M$451M
Total assets$852M$780M$870M$964M$991M$910M$967M$907M$905M$913M$926M$916M
Liabilities
Accounts payable$19.3M$33.1M$25.7M$20.4M$31.7M$27.5M$28.5M$32M$31.2M$22.2M$37.5M$26.2M
Accrued expenses$61.2M$34.8M$46.4M$25M$74.8M$31.9M$84.7M$89.1M$82.9M$0$88.1M$78M
Short-term debt$0$0$0$0$0$0$1M$1M$1M$4.04M$1M$0
Other current liabilities$0$34.6M$0$36.8M$0$50M$0$0$4.36M$112M$0$0
Current liabilities$91M$110M$83.2M$93.6M$118M$122M$123M$129M$126M$138M$129M$107M
Long-term debt$1M$1M$1M$1M$1M$1M$0$0$0$0$43.9M$0
Lease obligations (non-current)$68M$67.1M$72.3M$69.2M$66.4M$44.4M$44.2M$45.1M$45.2M$44.4M$0$43.3M
Deferred tax liabilities$18.3M$17.3M$33.3M$31.9M$32.2M$32.3M$32M$34.7M$31.7M$31.8M$30.6M$29.3M
Non-current liabilities$87.4M$85.4M$107M$102M$99.6M$77.7M$76.2M$79.8M$76.9M$76.2M$74.5M$72.6M
Total liabilities$178M$196M$190M$196M$218M$200M$199M$209M$203M$215M$204M$179M
Equity
Common stock & paid-in capital$11K$11K$12K$12K$13K$13K$14K$14K$16K$17K$18K$19K
Retained earnings-$1.9B-$2.01B-$2.13B-$2.22B-$2.31B-$2.38B-$2.5B-$2.61B-$2.7B-$2.78B-$2.85B-$2.9B
Accumulated other comprehensive income-$9.1M$2.53M$116K$526K$16.2M-$1.05M$6.29M$20.9M$16.1M$16.4M$12.7M$13.1M
Shareholders' equity$674M$585M$680M$769M$773M$710M$768M$698M$702M$699M$722M$736M
Debt
Total debt (incl. leases)$79.5M$75.9M$84.4M$81.7M$78.9M$58.3M$53.7M$53.2M$52.5M$48.4M$47.8M$46M
Net debt (debt - cash)-$188M-$39M-$49.8M-$147M-$85.2M-$57.4M-$118M-$79.3M-$106M-$115M-$149M-$64.8M

Standardised from the company's filings; outflows and costs keep the sign the provider reports. Hover a period for its end date. Amounts in USD.

Cash, investments and debt

quarter ends

The other statements

Sources

Statements, segment revenue, metrics and estimates are standardised from the company's filings. Segment profits and every reported line: SEC EDGAR (XBRL). Filings read: 10-Q 2026-06-30, 10-Q 2026-03-31, 10-K 2025-12-31, 10-Q 2025-09-30, 10-Q 2025-06-30, 10-Q 2025-03-31, 10-K 2024-12-31, 10-Q 2024-09-30, 10-Q 2024-06-30

Data as of 2026-11-02